||common in complete genomics
news rs4648261 was linked with a reduction in colorectal cancer risk of between 40 to 68 percent. Furthermore, characterizing patients by two SNPs in COX2 suggested that only a subset of patients would derive benefit from NSAID use.
The article notes a paper from AE. Coghill, C. Ulrich where a variety of COX2 genes PTGS-1 variants were associated with CRC survival. One, G>A intron 9 (rs1213266), was associated with ~50% lower CRC mortality (HRAA/AG vs. GG:0.48; 95% CI 0.25-0.93). Three variants, including L237M, resulted in significantly elevated CRC mortality risk, with hazard ratios ranging from approximately 1.5-2.0. Two variants in IkappaBKbeta, including R526Q, were significantly associated with CRC survival.
[PMID 19820421] The Effect of Genetic Polymorphisms of Cyclooxygenase 2 on Acute Pancreatitis in Turkey
[PMID 20676755] Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study
[PMID 21705955] Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility
[PMID 22551325] No Association of nineteen COX-2 gene variants to preclinical markers of atherosclerosis The Cardiovascular Risk in Young Finns Study